Concise Review: Immune Recognition of Induced Pluripotent Stem Cells§

Authors

  • Ashleigh S. Boyd,

    Corresponding author
    1. NIH Center of Biomedical Research Excellence (COBRE) in Stem Cell Biology, Roger Williams Medical Center, Boston University School of Medicine, Providence, Rhode Island, USA
    2. Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA
    3. Center for Regenerative Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    • NIH COBRE at Roger Williams Medical Center, Boston University School of Medicine, Prior Office 207.1, 825 Chalkstone Ave, Providence, Rhode Island 02908, USA
    Search for more papers by this author
    • Telephone: 1-401-456-5312; Fax: 1-401-456-5759

  • Neil P. Rodrigues,

    1. NIH Center of Biomedical Research Excellence (COBRE) in Stem Cell Biology, Roger Williams Medical Center, Boston University School of Medicine, Providence, Rhode Island, USA
    2. Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA
    3. Center for Regenerative Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Search for more papers by this author
  • Kathy O. Lui,

    1. Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Search for more papers by this author
  • Xuemei Fu,

    1. Section of Molecular Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, California, USA
    2. Chengdu Women's & Children's Central Hospital, Chengdu, Sichuan, China
    Search for more papers by this author
  • Yang Xu

    Corresponding author
    1. Section of Molecular Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, California, USA
    • Section of Molecular Biology, Division of Biological Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA
    Search for more papers by this author
    • Telephone: 1-858-822-1084; Fax: 1-858-534-0053


  • Author contributions: A.S.B.: conception and design, wrote manuscript, conceived and prepared figures, and final approval of manuscript; N.P.R.: conception and design, wrote manuscript, and final approval of manuscript; K.O.L.: prepared figures and reviewed manuscript; X.F.: contributed to writing manuscript; Y.X.: conception and design, contributed to writing manuscript and final approval of manuscript. A.S.B. and N.P.R. contributed equally to this article.

  • Disclosure of potential conflicts of interest is found at the end of this article.

  • §

    First published online in STEM CELLSEXPRESS March 14, 2012.

Abstract

Autologous-induced pluripotent stem cells (iPSCs) may eventually be used in cell replacement therapies to treat a wide range of diseases and have been touted as a solution to the vexing problem of immune rejection in this context. Emerging evidence suggests, however, that ostensibly histocompatible iPSCs may be rejected following transplantation. Here, we review the mechanisms that contribute to immunogenicity in iPSCs and forward approaches to permit their acceptance in potential cell replacement therapies. STEM CELLS 2012;30:797–803

Ancillary